2. Search Result
Search Result
Isoforms Recommended: RIPK2
Results for "

RIPK2

" in MedChemExpress (MCE) Product Catalog:

39

Inhibitors & Agonists

1

Recombinant Proteins

1

Antibodies

3

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-136789
    Tuxobertinib
    1 Publications Verification

    BDTX-189

    		 EGFR Cancer
    Tuxobertinib (BDTX-189) is a potent, orally active and selective inhibitor of allosteric EGFR and HER2 oncogenic mutations, including EGFR/HER2 exon 20 insertion mutants. Tuxobertinib shows KDs of 0.2, 0.76, 13 and 1.2 nM for EGFR, HER2, BLK and RIPK2, reapectively. Anticancer activity .
    Tuxobertinib
  • HY-18937
    WEHI-345
    3 Publications Verification

    		 RIP kinase Cancer
    WEHI-345 is a potent and selective RIPK2 kinase inhibitor with an IC50 of 0.13 μM, which delays RIPK2 ubiquitylation and NF-κB activation on oligomerization domain (NOD) stimulation .
    WEHI-345
  • HY-111866
    PROTAC RIPK degrader-2
    1 Publications Verification

    		 PROTACs RIP kinase Metabolic Disease Cancer
    PROTAC RIPK degraders -2 is a non-peptide PROTAC based on von Hippel-Lindau and targets serine-threonine kinase RIPK2, which is highly selective to the degradation of RIPK2. PROTAC RIPK degrader-2 acts as an activator to increase cell death and activate ion channels in cancer cells. PROTAC RIPK degrader-2 also can inhibit protein interactions, such as receptors and ligands, involved in a variety of diseases, such as cancer and diabetes [2].
    PROTAC RIPK degrader-2
  • HY-115630
    cRIPGBM chloride

    		RIP kinase Caspase Apoptosis Cancer
    cRIPGBM chloride, an orally active, proapoptotic derivative. cRIPGBM can be generated from glioblastoma multiforme (GBM) cancer stem cells (CSCs). cRIPGBM(chloride) targets to receptor-interacting protein kinase 2 (RIPK2) to induce caspase 1-dependent apoptosis. cRIPGBM(chloride) suppresses the formation of RIPK2/TAK1 (prosurvival complex), and increases the formation of RIPK2/caspase 1 (proapoptotic complex). cRIPGBM(chloride) exerts potent anti-tumor activity in vivo in animal models .
    cRIPGBM chloride
  • HY-131064
    RIPK3-IN-1
    1 Publications Verification

    		 RIP kinase Inflammation/Immunology
    RIPK3-IN-1 is a RIPK3 type II DFG-out inhibitor with an IC50 of 9.1 nM. RIPK3-IN-1 inhibits RIPK1 and RIPK2 with IC50s of 5.5 and >10 μM. RIPK3-IN-1 is also a c-Met kinase inhibitor with an IC50 of 1.1 μM .
    RIPK3-IN-1
  • HY-124793
    GAK inhibitor 49
    1 Publications Verification

    		 Cyclin G-associated Kinase (GAK) Infection
    GAK inhibitor 49 is a potent, ATP-competitive and highly selective cyclin G associated kinase (GAK) inhibitor with a Ki of 0.54 nM and a cell IC50 of 56 nM. GAK inhibitor 49 also shows binding to RIPK2 .
    GAK inhibitor 49
  • HY-19628
    OD36

    		RIP kinase TGF-β Receptor Inflammation/Immunology
    OD36 is a RIPK2 inhibitor with an IC50 of 5.3 nM. OD36 is a macrocyclic inhibitor with potent binding to the ALK2 kinase ATP pocket. OD36 shows ALK2-directed activity with KDs of 37 nM [2].
    OD36
  • HY-155782
    Zharp2-1

    		RIP kinase Inflammation/Immunology
    Zharp2-1 is an oral effective RIPK2 inhibitor, highly associated with inflammatory bowel disease (IBD). Zharp2-1 blocker muramyl dipeptide (MDP) induces growth of mononuclear cells and induces inflammatory cell factor infection. Zharp2-1 attenuates MDP-induced small inguinal peritonitis, or ameliorates by DNBS-induced large inguinal conjunctivitis .
    Zharp2-1
  • HY-157325
    RIPK2-IN-5

    		RIP kinase Inflammation/Immunology
    RIPK2-IN-5 (compound 14) is a high affinity and excellent selectivity RIPK2 inhibitor with an IC50 value of 5.1nM. RIPK2-IN-5 has cellular anti-inflammatory effect and can reduce the secretion of MDP-induced TNF-α with a dose-dependent manner. RIPK2-IN-5 shows moderate stability in human liver microsome. RIPK2-IN-5 can be used for the research of immune diseases .
    RIPK2-IN-5
  • HY-107978
    RIPK-IN-4
    2 Publications Verification

    		 RIP kinase Inflammation/Immunology
    RIPK-IN-4 is a selective RIPK2 inhibitor with an IC50 value of 3 nM. RIPK-IN-4 can be used for the research of inflammatory diseases .
    RIPK-IN-4
  • HY-122665
    HTH-01-091

    		MELK DYRK Pim mTOR CDK GSK-3 RIP kinase Cancer
    HTH-01-091 is a potent and selective maternal embryonic leucine zipper kinase (MELK) inhibitor, with an IC50 of 10.5 nM. HTH-01-091 also inhibits PIM1/2/3, RIPK2, DYRK3, smMLCK and CLK2. HTH-01-091 can be uesd for breast cancer research .
    HTH-01-091
  • HY-146694
    RIPK2-IN-1

    		RIP kinase Anaplastic lymphoma kinase (ALK) Inflammation/Immunology
    RIPK2-IN-1 (compound 18f) is a potent RIPK2 inhibitor with an IC50 of 51 nM. RIPK2-IN-1 inhibits ALK2 with an IC50 of 5 nM. RIPK2-IN-1 has an IC50 of 390 nM on RIPK2/NOD2 in cell assay .
    RIPK2-IN-1
  • HY-157456
    RIPK1-IN-19

    		RIP kinase Inflammation/Immunology
    RIPK1-IN-19 is a selective RIPK1 inhibitor (IC50=15 nM). RIPK1-IN-19 does not show obvious activity against RIPK2, RIPK3, and RIPK4. RIPK1-IN-19 displays potent protective activity in TNFα-induced systemic inflammatory response syndrome (SIRS) model and Imiquimod (IMQ)-induced psoriasis model. RIPK1-IN-19 can be used in research on inflammation and immune system diseases .
    RIPK1-IN-19
  • HY-136010
    RIP2 Kinase Inhibitor 4

    		RIP kinase PROTACs Inflammation/Immunology
    RIP2 Kinase Inhibitor 4 is a potent and selective RIPK2 PROTAC. RIP2 Kinase Inhibitor 4 effectively degrades RIPK2 (pIC50 of 8) and inhibits the release of related TNF-α .
    RIP2 Kinase Inhibitor 4
  • HY-157309
    RIPK2-IN-4

    		RIP kinase Cancer
    RIPK2-IN-4 is a potent and specific RIPK2 inhibitor with an IC50 value of 5 nM .
    RIPK2-IN-4
  • HY-171592
    RIPK2-IN-7

    		RIP kinase NOD-like Receptor (NLR) TNF Receptor Inflammation/Immunology
    RIPK2-IN-7 (Compound 10w) is an orally active, selective RIPK2 inhibitor (IC50: 0.6 nM). RIPK2-IN-7 inhibits RIPK2 kinase activity, blocks the nucleotide-binding oligomerization domain (NOD) signaling pathway, and reduces the production of inflammatory factors (such as TNFα). RIPK2-IN-7 can be used in the study of inflammatory bowel disease (IBD) .
    RIPK2-IN-7
  • HY-RS11996
    Ripk2 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) RIP kinase Others

    Ripk2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ripk2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Ripk2 Mouse Pre-designed siRNA Set A
    Ripk2 Mouse Pre-designed siRNA Set A
  • HY-RS11995
    RIPK2 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    RIPK2 Human Pre-designed siRNA Set A contains three designed siRNAs for RIPK2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    RIPK2 Human Pre-designed siRNA Set A
    RIPK2 Human Pre-designed siRNA Set A
  • HY-RS11997
    Ripk2 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) RIP kinase Others

    Ripk2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Ripk2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Ripk2 Rat Pre-designed siRNA Set A
    Ripk2 Rat Pre-designed siRNA Set A
  • HY-19628A
    OD36 hydrochloride

    		RIP kinase TGF-β Receptor Inflammation/Immunology
    OD36hydrochloride is a RIPK2 inhibitor with an IC50 of 5.3 nM. OD36 hydrochloride is a macrocyclic inhibitor with potent binding to the ALK2 kinase ATP pocket. OD36 hydrochloride shows ALK2-directed activity with KDs of 37 nM [2].
    OD36 hydrochloride
  • HY-100112
    WEHI-345 analog

    		RIP kinase Others
    WEHI-345 analog is the analog of WEHI-345. WEHI-345 is a potent and selective RIPK2 kinase inhibitor with an IC50 of 0.13 μM, which delays RIPK2 ubiquitylation and NF-κB activation on oligomerization domain (NOD) stimulation .
    WEHI-345 analog
  • HY-175026
    RIPK2-IN-8

    		RIP kinase NF-κB p38 MAPK Interleukin Related Inflammation/Immunology
    RIPK2-IN-8 is an orally active and highly selective RIPK2 inhibitor (IC50 = 11 nM). RIPK2-IN-8 is highly selective for RIPK2 over RIPK1 (IC50 > 30,000 nM) and has a moderate inhibitory effect on RIPK3 (IC50 = 44.61 nM). RIPK2-IN-8 inhibits the NOD2-RIPK2 signaling pathway and the expression of the inflammatory cytokines IL-6 and TNFα, thereby exerting anti-inflammatory effects. RIPK2-IN-8 has demonstrated anti-inflammatory and hepatoprotective effects in an acute liver injury (ALI) model and can be used in ALI research .
    RIPK2-IN-8
  • HY-124793A
    GAK inhibitor 49 hydrochloride
    1 Publications Verification

    		 Cyclin G-associated Kinase (GAK) Infection
    GAK inhibitor 49 hydrochloride is a potent, ATP-competitive and highly selective cyclin G associated kinase (GAK) inhibitor with a Ki of 0.54 nM and a cell IC50 of 56 nM. GAK inhibitor 49 hydrochloride also shows binding to RIPK2 .
    GAK inhibitor 49 hydrochloride
  • HY-147235
    RIPK2-IN-2

    		RIP kinase PROTACs Infection
    RIPK2-IN-2 (example 25) is a RIP2 kinase PROTAC inhibitor. RIPK2-IN-2 can block RIP2-dependent proinflammatory signaling, regulated RIP2 kinase activity in auto inflammatory diseases .
    RIPK2-IN-2
  • HY-122665A
    HTH-01-091 TFA

    		MELK DYRK Pim mTOR CDK GSK-3 RIP kinase Cancer
    HTH-01-091 TFA is a potent and selective maternal embryonic leucine zipper kinase (MELK) inhibitor, with an IC50 of 10.5 nM. HTH-01-091 TFA also inhibits PIM1/2/3, RIPK2, DYRK3, smMLCK and CLK2. HTH-01-091 TFA can be uesd for breast cancer research .
    HTH-01-091 TFA
  • HY-124643
    RIPK2-IN-3

    		RIP kinase Cancer
    RIPK2-IN-3 (FCG806791773) is a RIPK2 inhibitor. RIPK2-IN-3 inhibits recombinant truncated RIPK2 with an IC50 of 6.39 μM. RIPK2-IN-3 can be used for research of inflammation and cancer .
    RIPK2-IN-3
  • HY-137340
    WH-10417-099

    		PROTACs Casein Kinase Cancer
    WH-10417-099 is a CRBN-based PROTAC multi-kinase degrader that induces the degradation of the maximum number of unique kinases (over 125 unique kinases, such as CSNK1E and PI3Kγ) simultaneously. WH-10417-099 induces protein degradation via the ubiquitin biotinylation (E-STUB) pathway, exhibits synergistic effects with SB-405483 (HY-W1135319). The E3 ligase ligand and linker of WH-10417-099 can form the conjugate Pomalidomide 4'-PEG5-acid (HY-131647) [2].
    WH-10417-099
  • HY-123924
    CSLP37

    		RIP kinase Inflammation/Immunology
    CSLP37 is a selective RIPK2 inhibitor with an IC50 of 16.3 nM. CSLP37 shows no inhibitory activity against RIPK1 and RIPK3. CSLP37 displays potent suppression of cellular NOD1 and NOD2 responses .
    CSLP37
  • HY-171986
    RIPK3-IN-6

    		RIP kinase Cancer
    RIPK3-IN-6 (compound 1) is a type I RIPK3 inhibitor with poor selectivity for the RIPK family, especially for RIPK2 activity .
    RIPK3-IN-6
  • HY-168567
    RIPK2-IN-6

    		RIP kinase NF-κB p38 MAPK Inflammation/Immunology
    RIPK2-IN-6 (Compound 15a) is an inhibitor for RIPK, that inhibits the phosphorylation of RIPK2, and thus inhibits the NF-κB and MAPK signaling pathways. RIPK2-IN-6 exhibits anti-inflammatory and anti-fibrotic activities in Dextran sodium sulfate (HY-116282C)-induced mice colitis models .
    RIPK2-IN-6
  • HY-159965
    NOD1-RIPK2-IN-1

    		NOD-like Receptor (NLR) RIP kinase Interleukin Related Inflammation/Immunology
    NOD1-RIPK2-IN-1 (Compound 37) is a NOD1-RIPK2 signaling pathway inhibitor with IC50 values of 42 nM and 1.52 nM for NOD1 and RIPK2, respectively. NOD1-RIPK2-IN-1 reduces the secretion of the pro-inflammatory cytokine IL-8 and can be used in the research of inflammation and immune-related diseases .
    NOD1-RIPK2-IN-1
  • HY-173454
    RIPK2/3-IN-2

    		RIP kinase Inflammation/Immunology
    RIPK2/3-IN-2 (29) is a dual RIPK2 and RIPK3 inhibitor, with IC50 values of 12 nM and 18 nM, respectively. RIPK2/3-IN-2 (29) induces necroptosis, with an EC50 of 0.16 μM .
    RIPK2/3-IN-2
  • HY-155151
    RIPK2/3-IN-1

    		RIP kinase Inflammation/Immunology
    RIPK2/3-IN-1 is a potent dual RIPK2/3 kinases inhibitor with IC50 values of 3 nM and 117 nM, respectively. RIPK2/3-IN-1 is against RIPK2 with IC50 value 14 nM in 14-TriLAN-Gly/NOD1 THP-1 cell-based NF-κB reporter assay .
    RIPK2/3-IN-1
  • HY-125466
    cRIPGBM

    		RIP kinase Apoptosis Caspase Cancer
    cRIPGBM, a proapoptotic derivative of RIPGBM, a cell type-selective inducer of apoptosis in GBM cancer stem cells (CSCs) by binding to receptor-interacting protein kinase 2 (RIPK2), with an EC50 of 68 nM in GBM-1 cells .
    cRIPGBM
  • HY-168024
    NOD1/2-IN-1

    		RIP kinase NOD-like Receptor (NLR) Inflammation/Immunology
    NOD1/2-IN-1 (Compound 18) is a potent RIPK2 inhibitor with an IC50 value of 1.4 nM, as determined by the ADP-Glo assay. NOD1/2-IN-1 blocks the production of pro-inflammatory cytokines by inhibiting the NOD1/NOD2 pathways, with IC50 values of 18 nM and 170 nM for NOD1 and NOD2, respectively, thereby reducing inflammatory responses. NOD1/2-IN-1 can be used in studies related to colitis .
    NOD1/2-IN-1
  • HY-168023
    NOD1-IN-1

    		NOD-like Receptor (NLR) Inflammation/Immunology
    NOD1/-IN-1 (Compound 2) is a potent RIPK2 inhibitor with an IC50 value of 0.65 nM determined by ADP-Glo assays. NOD1/-IN-1 selectively inhibits the NOD1 pathway (with an IC50 of 33 nM for NOD1), blocking the production of pro-inflammatory cytokines and thereby reducing inflammation. NOD1/-IN-1 is applicable for research in the field of colitis .
    NOD1-IN-1
  • HY-123925
    CSLP43

    		RIP kinase IAP NOD-like Receptor (NLR) Inflammation/Immunology
    CSLP43 is a selective RIPK2 and XIAP inhibitor with an IC50 of 19.9 nM against human RIPK2. CSLP43 binds to the ATP-binding pocket of RIPK2 and disrupts the interaction between RIPK2 and the BIR2 domain of XIAP or cIAP1. CSLP43 inhibits RIPK2 ubiquitination, NOD1-dependent inflammatory signaling pathways, NOD2-dependent inflammatory signaling pathways, as well as NF-κB activation associated with NOD agonists. CSLP43 is selective for the NOD1/NOD2 signaling pathway and does not inhibit the kinase activity of RIPK1 or RIPK3. CSLP43 is applicable to research related to Crohn's disease, Blau syndrome, early-onset sarcoidosis and early-onset inflammatory bowel disease .
    CSLP43
  • HY-183717
    M4K3233

    		Cancer
    M4K3233 is a selective ALK2 PROTAC degrader with a pDC50 of 7.3 and a pIC50 of 6.6. M4K3233 recruits CRBN to form a ternary complex with ALK2, mediating ALK2 degradation via the proteasomal and lysosomal pathways. M4K3233 induces moderate downregulation of RIPK2 and significant downregulation of SIK3 in mammalian cells. M4K3233 is applicable to research related to glioblastoma .
    M4K3233
  • HY-107978R
    RIPK-IN-4 (Standard)

    		Reference Standards RIP kinase Inflammation/Immunology
    RIPK-IN-4 (Standard) is the analytical standard of RIPK-IN-4 (HY-107978). This product is intended for research and analytical applications. RIPK-IN-4 is a selective RIPK2 inhibitor with an IC50 value of 3 nM. RIPK-IN-4 can be used for the research of inflammatory diseases .
    RIPK-IN-4 (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: